Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06096974
Title	Pan-RAS Inhibitor YL-17231 in Patients With Advanced Solid Tumors Harboring Mutations in KRAS, HRAS, or NRAS
Recruitment	Not yet recruiting
Gender	both
Phase	Phase I
Variant Requirements	Yes
Sponsors	Shanghai YingLi Pharmaceutical Co. Ltd.
Indications	Advanced Solid Tumor
Therapies	TEB-17231
Age Groups:	adult \| senior
Covered Countries	USA